Texas Permanent School Fund Acquires Shares of 33,694 Arcus Biosciences, Inc. (NYSE:RCUS)

Texas Permanent School Fund acquired a new stake in Arcus Biosciences, Inc. (NYSE:RCUSGet Rating) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 33,694 shares of the company’s stock, valued at approximately $854,000.

A number of other large investors have also recently made changes to their positions in RCUS. Vanguard Group Inc. raised its holdings in shares of Arcus Biosciences by 2.5% in the first quarter. Vanguard Group Inc. now owns 3,512,114 shares of the company’s stock valued at $110,843,000 after purchasing an additional 85,778 shares during the last quarter. State Street Corp raised its holdings in shares of Arcus Biosciences by 25.5% in the first quarter. State Street Corp now owns 2,749,919 shares of the company’s stock valued at $86,787,000 after purchasing an additional 557,988 shares during the last quarter. Decheng Capital Management III Cayman LLC purchased a new stake in shares of Arcus Biosciences in the first quarter valued at about $27,451,000. Dimensional Fund Advisors LP raised its holdings in shares of Arcus Biosciences by 77.0% in the first quarter. Dimensional Fund Advisors LP now owns 437,969 shares of the company’s stock valued at $13,826,000 after purchasing an additional 190,527 shares during the last quarter. Finally, Sectoral Asset Management Inc. raised its holdings in shares of Arcus Biosciences by 19.5% in the first quarter. Sectoral Asset Management Inc. now owns 338,480 shares of the company’s stock valued at $10,682,000 after purchasing an additional 55,270 shares during the last quarter. 72.61% of the stock is owned by institutional investors.

Insider Activity

In other news, COO Jennifer Jarrett sold 12,677 shares of the business’s stock in a transaction that occurred on Friday, September 16th. The shares were sold at an average price of $26.28, for a total value of $333,151.56. Following the sale, the chief operating officer now owns 130,942 shares of the company’s stock, valued at $3,441,155.76. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 12.70% of the company’s stock.

Arcus Biosciences Stock Down 5.0 %

NYSE RCUS opened at $27.31 on Monday. The company’s 50 day moving average is $26.67 and its 200-day moving average is $25.10. Arcus Biosciences, Inc. has a 12-month low of $16.74 and a 12-month high of $49.10. The firm has a market cap of $1.98 billion, a P/E ratio of 29.68 and a beta of 0.61.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Bank of America assumed coverage on shares of Arcus Biosciences in a report on Friday. They issued a “neutral” rating and a $33.00 target price for the company. Wedbush decreased their price objective on shares of Arcus Biosciences from $42.00 to $36.00 and set an “outperform” rating for the company in a report on Thursday, August 4th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcus Biosciences in a report on Wednesday, September 21st. Citigroup decreased their price objective on shares of Arcus Biosciences from $48.00 to $40.00 in a report on Thursday, August 18th. Finally, SVB Leerink decreased their price objective on shares of Arcus Biosciences from $40.00 to $38.00 and set an “outperform” rating for the company in a report on Thursday, November 3rd. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $41.00.

Arcus Biosciences Company Profile

(Get Rating)

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy.

Read More

Want to see what other hedge funds are holding RCUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcus Biosciences, Inc. (NYSE:RCUSGet Rating).

Institutional Ownership by Quarter for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.